The Food and Drug Administration is looking to shift away from policies dating back decades of having outside experts and panels review new drug applications. These external committees have been used since the 1970s in order to better advise health officials facing difficult decisions. Arthur Allen, senior correspondent for KFF Health News, joined CBS News to discuss.
FDA looking to abandon expert reviews of new drugs

6